ARCHIVES

Phase II Elotuzumab Study Demonstrates 33 Months PFS

This article is from The Cancer Letter archive.

Vol. 36 No. 7 | July 26, 2013

Download PDF Visit The Full Archive

Related Articles

NCAB Hears Good News: FY 92 Budget Allows NCI To Increase Levels Of Most Programs

November 29, 1991

NCAB Settles New Touchy PDQ Issues

June 7, 1985

ACS Board Accepts Hammer’s ffer, Will Support Construction Survey

February 17, 1984

In Radio Address, Clinton Outlines Administration Priorities

October 2, 1998

Conte Withdraws Amendments Adding $40 Million for Flood Promise To Compromise

June 24, 1977

Degarelix Active In Phase II Trial In Prostate Cancer

October 29, 2004